<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03617263</url>
  </required_header>
  <id_info>
    <org_study_id>SARO.17.009</org_study_id>
    <nct_id>NCT03617263</nct_id>
  </id_info>
  <brief_title>Saroglitazar Magnesium 4 mg in the Treatment of NAFLD in Women With PCOS (EVIDENCES VII)</brief_title>
  <official_title>Phase 2A, Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Saroglitazar Mg 4 mg Tablet Vs Placebo for Treating NAFLD in Women With Polycystic Ovary Syndrome (PCOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zydus Discovery DMCC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zydus Discovery DMCC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed
      to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well
      characterized PCOS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed
      to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well
      characterized PCOS. \

      The study will be conducted over a period of up to 34 weeks and will include Screening (Days
      -28 to -7) Phase, a 24-week Treatment Phase following randomization on Day 1.

      The primary endpoint of the study is change in hepatic fat content from baseline following 24
      weeks of treatment as measured by MRI-PDFF.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2018</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic fat content</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in hepatic fat content from baseline following 24 weeks of treatment as measured by MRI-PDFF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver enzymes/LFTs</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Changes from baseline to week 12 and week 24 in liver enzymes/LFTs: ALT, AST, ALP,GGT, serum protein, albumin and total bilirubin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Changes from baseline to week 12 and week 24 in insulin resistance as measured by HOMA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of liver injury</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes from baseline to week 24 in markers of liver injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver fibrosis</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes from baseline to week 24 in fibrosis including CK-18, hs-CRP, and TNFα</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver stiffness</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes from baseline to week 24 in liver stiffness measured by transient elastography/FibroScan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Controlled attenuation parameter</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes from baseline to week 24 in controlled attenuation parameter measured by transient elastography/ FibroScan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Changes from baseline to week 12 and week 24 in BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Changes from baseline to week 12 and week 24 in waist circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI-derived measures of total liver fat index (It will be calculated as the product of liver volume and the liver mean proton-density fat fraction across all liver segments)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes from baseline to week 24 in MRI-derived measures of total liver fat index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI-derived measures of total liver volume (Liver volume will be calculated after complete segmentation by summing the liver surface area at each segmented slice, and then multiplying this sum by individual slice thickness, in millilitres [mL])</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes from baseline to week 24 in MRI-derived measures of total liver volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid and lipoprotein levels</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Changes from baseline to week 12 and week 24 in lipid and lipoprotein levels: TG, TC, HDL, LDL, sdLDL, VLDL, apolipoprotein A and apolipoprotein B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SHBG level</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Changes from baseline to week 12 and week 24 in SHBG level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian function</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Changes from baseline to week 12 and week 24 in ovarian function (Total testosterone, 17-hydroxyprogesterone, free testosterone, luteinizing hormone, follicle-stimulating hormone, LH-to-FSH ratio and estradiol)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free androgen index ( Total testosterone level divided by the sex hormone binding globulin (SHBG) level, and then multiplying by a constant, usually 100. The concentrations of testosterone and SHBG are normally measured in nanomols per liter.</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Changes from baseline to week 12 and week 24 in free androgen index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma concentration [Cmax] (For Single Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach peak Plasma concentration [Tmax] (For Single Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under Plasma concentration vs. time curve till the last time point [AUC0-t] (For Single Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under Plasma concentration vs. time curve extrapolated to the infinity (AUC0-∞) after first dose (For Single Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration vs. time curve in a 24 h dosing interval (AUCtau) after first dose (For Single Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant [Kel] (For Single Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life [tHalf] (For Single Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of distribution [Vd/F] (For Single Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance [CL/F] (For Single Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma concentration [Cmax,ss] (For Multiple Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach peak Plasma concentration [Tmax,ss] (For Multiple Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration vs. time curve in a 24 h dosing interval (AUCtau) after last dose (For Multiple Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant [Kel,ss] (For Multiple Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life [thalf,ss] (For Multiple Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of distribution [Vd/F,ss] (For Multiple Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance [CL/F,ss] (For Multiple Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal or Trough plasma concentration [Cmin] (For Multiple Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluctuation index (For Multiple Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index calculated as a ratio of AUCtau (last dose)/AUCtau (first dose) (For Multiple Dose)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pharmacokinetics of Saroglitazar following last dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease in Women With PCOS</condition>
  <arm_group>
    <arm_group_label>Saroglitazar Magnesium 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saroglitazar Magnesium once daily in the morning before breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet once daily in the morning before breakfast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar Magnesium 4 mg Tablet</intervention_name>
    <description>Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.</description>
    <arm_group_label>Saroglitazar Magnesium 4 mg</arm_group_label>
    <other_name>Not any</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Not any</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females, 18 to 45 years of age.

          -  Previously confirmed diagnosis of PCOS:

               1. oligo-and/or anovulation;

               2. hyperandrogenism (clinical and/or biochemical);

               3. polycystic ovary morphology on ultrasonography

          -  Evidence of NAFLD within 6 months prior to the Screening Visit (Visit 1).

          -  Alanine transaminase ≥ 38 U/L at Visit 1. Visit 2 ALT must not increase &gt;30% from
             Visit 1.

          -  Hepatic fat fraction ≥10% by MRI-PDFF.

          -  Willingness to participate in the study.

          -  Ability to understand and give informed consent for participation.

          -  Woman who agrees to use the contraceptive methods.

        Exclusion Criteria:

          -  Presence of other chronic liver diseases (hepatitis B or C, autoimmune hepatitis,
             cholestatic liver disease, Wilsons disease, hemochromatosis, etc.).

          -  Average alcohol consumption ≥ 7 drinks per week for women in the 6 months prior to
             enrollment.

          -  Clinical, imaging, or histological evidence of cirrhosis.

          -  Patients who have used medications known to cause hepatic steatosis for more than 2
             weeks in the past year.

          -  Prior bariatric surgery.

          -  Weight loss of more than 5% in the 3 months preceding screening.

          -  Severe co-morbidities (e.g., advanced cardiac, renal, pulmonary, or psychiatric
             illness).

          -  Known allergy, sensitivity or intolerance to Saroglitazar Magnesium, comparator or
             formulation ingredients.

          -  Use of antidiabetic and lipid lowering medications if the dose is not stable for at
             least the 3 months preceding screening.

          -  Intake of Vitamin E (&gt;100 IU/day) or multivitamins containing Vitamin E (&gt;100 IU/day)
             3 months before enrollment.

          -  Use of drugs with potential effect on NAFLD/NASH in the 3 months prior to screening.

          -  Illicit substance abuse within the past 12 months.

          -  Pregnant or breast feeding females.

          -  Women with known Cushing syndrome or hyperprolactinemia.

          -  Refusal or inability to comply with the requirements of the protocol, for any reason,
             including scheduled clinic visits and laboratory tests.

          -  History of myopathies or evidence of active muscle diseases.

          -  History or current significant cardiovascular disease.

          -  History of malignancy.

          -  History of bladder disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deven Parmar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Zydus Discovery DMCC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Farheen Shaikh</last_name>
    <phone>+971-43998280</phone>
    <phone_ext>105</phone_ext>
    <email>farheen.arifahmed@zydusdiscovery.ae</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deven Parmar, MD</last_name>
    <phone>+971-43998280</phone>
    <phone_ext>105</phone_ext>
    <email>deven.parmar@zydusdiscovery.ae</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanin T Srisengfa</last_name>
      <phone>415-502-3725</phone>
      <email>yanin.srisengfa@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rayshawnda Davis</last_name>
      <phone>415-502-3725</phone>
      <email>rayshawnda.davis@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Monika Sarkar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Weber</last_name>
      <phone>317-278-6266</phone>
      <email>reginaw@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Dr. Niharika Samala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación Medico Biológica y Terapia Avanzada SC (CIMBYTA)</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44130</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Dr. Jose Eleuterio Gonzalez&quot;</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UBAM Unidad Biomédica Avanzada Monterrey</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro para el Desarrollo de la Medicina y de Asistencia Médica Especializada S.C.</name>
      <address>
        <city>Culiacán</city>
        <state>Sinaloa</state>
        <zip>80230</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Care and Research S.A. de C.V.</name>
      <address>
        <city>Mérida</city>
        <state>Yucatán</state>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CEMDEC S.A. de C.V. (Centero Mexicana Desarrollo de Estudios Clinicos)</name>
      <address>
        <city>Ciudad de mexico</city>
        <zip>06100</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kelley CE, Brown AJ, Diehl AM, Setji TL. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol. 2014 Oct 21;20(39):14172-84. doi: 10.3748/wjg.v20.i39.14172. Review.</citation>
    <PMID>25339805</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 23, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <keyword>PCOS</keyword>
  <keyword>Saroglitazar Magnesium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

